10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Nac1 (BTBD14B) Antibody (Center) Blocking peptide

Synthetic peptide
Catalog # BP1493c

Specification

Nac1 (BTBD14B) Antibody (Center) Blocking peptide - Product Information

Primary Accession Q96RE7

Nac1 (BTBD14B) Antibody (Center) Blocking peptide - Additional Information

Gene ID 112939

Other Names
Nucleus accumbens-associated protein 1, NAC-1, BTB/POZ domain-containing protein 14B, NACC1, BTBD14B, NAC1

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1493c was selected from the Center region of human BTBD14B. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Nac1 (BTBD14B) Antibody (Center) Blocking peptide - Protein Information

Name NACC1

Synonyms BTBD14B, NAC1

Function
Functions as a transcriptional repressor. Seems to function as a transcriptional corepressor in neuronal cells through recruitment of HDAC3 and HDAC4. Contributes to tumor progression, and tumor cell proliferation and survival. This may be mediated at least in part through repressing transcriptional activity of GADD45GIP1. Required for recruiting the proteasome from the nucleus to the cytoplasm and dendritic spines.

Cellular Location
Nucleus. Cytoplasm. Note=Distribution in the cytoplasm is dependent on phosphorylation.

Tissue Location
Overexpressed in several types of carcinomas including ovarian serous carcinomas. Expression levels positively correlate with tumor recurrence in ovarian serous carcinomas, and intense immunoreactivity in primary ovarian tumors predicts early recurrence. Up-regulated in ovarian carcinomas after chemotherapy, suggesting a role in development of chemotherapy resistance in ovarian cancer.

Nac1 (BTBD14B) Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

Nac1 (BTBD14B) Antibody (Center) Blocking peptide - Images

Nac1 (BTBD14B) Antibody (Center) Blocking peptide - Background

BTBD14B functions as a transcriptional corepressor in neuronal cells through recruitment of HDAC3 and HDAC4. In humans this protein is upregulated in a number of carcinomas and is localized in discrete nuclear bodies that correlate with tumour recurrence.

Nac1 (BTBD14B) Antibody (Center) Blocking peptide - References

Nakayama,K., Cancer Res. 67 (17), 8058-8064 (2007)Davidson,B., Hum. Pathol. 38 (7), 1030-1036 (2007)Nakayama,K., Proc. Natl. Acad. Sci. U.S.A. 103 (49), 18739-18744 (2006)